Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024
Combined Shareholders’ Meeting of 30 May 2018
You are now leaving the Ipsen group global website. To continue, please click on Continue?
